Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | H3B-6545 |
Synonyms | |
Therapy Description |
H3B-6545 is a selective estrogen receptor covalent antagonist (SERCA) that targets both wild-type and mutant ESR1, which may result in antitumor activity (PMID: 35642432). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
H3B-6545 | SERCA H3B6545|H3B 6545 | Hormone - Anti-estrogens 29 | H3B-6545 is a selective estrogen receptor covalent antagonist (SERCA) that targets both wild-type and mutant ESR1, which may result in antitumor activity (PMID: 35642432). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03250676 | Phase Ib/II | H3B-6545 | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | Completed | USA | GBR | FRA | 0 |